Matricelf Partners with Sheba Medical Center for Spinal Cord Injury Clinical Trials

Matricelf (TASE: MTLF) has announced a strategic collaboration with Sheba Medical Center to support its inaugural first-in-human clinical trial. The partnership focuses on advancing regenerative medicine therapies specifically designed for spinal cord injuries. The clinical program involves the development of autologous engineered neural tissue, a cutting-edge approach in the biotechnology sector. By collaborating with Sheba Medical Center, which is ranked 7th globally by Newsweek, Matricelf gains access to world-class clinical infrastructure and expertise. This milestone is expected to significantly reduce execution risks as the company transitions into the critical clinical phase. Investors view this move as a major step forward in validating Matricelf’s technology and its potential for future commercialization.

Sources:prnewswire.comnmidigital.comynetnews.commorningstar.com